Volasertib is primarily used in the field of oncology as a potent and selective inhibitor of Polo-like kinase 1 (PLK1), a key regulator of cell division. Its application is focused on targeting cancer cells, particularly in cases where uncontrolled cell proliferation is a hallmark, such as in acute myeloid leukemia (AML) and other solid tumors. By inhibiting PLK1, Volasertib disrupts the mitotic process, leading to cell cycle arrest and apoptosis in cancer cells. It has been investigated in clinical trials as a monotherapy and in combination with other chemotherapeutic agents to enhance treatment efficacy. Its potential lies in addressing cancers with poor prognosis or resistance to conventional therapies, offering a targeted approach to inhibit tumor growth.